Literature DB >> 15742437

Inflammation in patients with lupus anticoagulant and implications for thrombosis.

Thomas Sailer1, Rainer Vormittag, Ingrid Pabinger, Thomas Vukovich, Stephan Lehr, Peter Quehenberger, Simon Panzer, Klaus Lechner, Claudia Zoghlami-Rintelen.   

Abstract

OBJECTIVE: The underlying mechanism of the prothrombotic state associated with the lupus anticoagulant (LAC) has not been fully elucidated. Evidence suggests involvement of inflammation in arterial and venous thrombosis, and it may be hypothesized that subclinical inflammation aggravates the tendency to thrombosis in patients with LAC.
METHODS: Levels of high sensitivity C-reactive protein (hs-CRP), fibrinogen, and factor VIII (VIII) were measured in 38 patients with LAC and a history of thrombosis, 27 with LAC and no history of thrombosis, and 33 healthy controls.
RESULTS: Hs-CRP, fibrinogen, and factor VIII levels were significantly higher in patients with LAC with thrombosis (hs-CRP median = 0.3 mg/dl, interquartile range, IQR, 0.11-0.62, p < 0.001 vs controls; fibrinogen mean = 395 +/- 90 SD mg/dl, p < 0.001; factor VIII mean = 181 +/- 50%, p = 0.005) as well as in those without thrombosis (median = 0.21, IQR 0.10-0.12, p < 0.001; mean = 378 +/- 91, p = 0.003; mean = 179 +/- 39, p = 0.015) compared to controls (median = 0.07, IQR 0.03-0.12; mean = 308 +/- 48; mean = 137 +/- 39). After adjustment for age, body mass index, smoking status, and blood group (only for factor VIII) the differences between LAC groups and controls remained significant, except for the comparison of fibrinogen between patients without thrombosis and controls. The association between LAC and markers of inflammation was confirmed using linear regression analysis. Markers of systemic inflammation did not differentiate between LAC patients with and without thrombosis (p = 0.829 for hs-CRP, p = 0.649 for fibrinogen, p = 0.996 for factor VIII).
CONCLUSION: Our results show that LAC is associated with an inflammatory state. However, there was no evidence for an association between inflammatory markers and thromboembolism in patients with LAC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15742437

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM.

Authors:  Amit K Maiti; Xana Kim-Howard; Prasenjeet Motghare; Vandana Pradhan; Kek Heng Chua; Celi Sun; María Teresa Arango-Guerrero; Kanjaksha Ghosh; Timothy B Niewold; John B Harley; Juan-Manual Anaya; Loren L Looger; Swapan K Nath
Journal:  Hum Mol Genet       Date:  2014-03-07       Impact factor: 6.150

2.  8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study.

Authors:  Savino Sciascia; Dario Roccatello; Maria Tiziana Bertero; Debora Di Simone; Domenico Cosseddu; Antonella Vaccarino; Mario Bazzan; Daniela Rossi; Cesar Garcia-Fernandez; Leticia Ceberio; Stefania Stella; Elisa Menegatti; Simone Baldovino
Journal:  Inflamm Res       Date:  2012-05-26       Impact factor: 4.575

Review 3.  Systemic antiphospholipid syndrome and atherosclerosis.

Authors:  Luis J Jara; Gabriela Medina; Olga Vera-Lastra
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

4.  High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus.

Authors:  Shin-Seok Lee; Sukhminder Singh; Kimberly Link; Michelle Petri
Journal:  Semin Arthritis Rheum       Date:  2008-01-25       Impact factor: 5.532

5.  Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome.

Authors:  Yonatan Edel; Vitaly Kliminski; Elisheva Pokroy-Shapira; Shirly Oren; Ariela Dortort Lazar; Yael Pri-Paz Basson; Mohammad Egbaria; Yair Molad
Journal:  Arthritis Res Ther       Date:  2019-01-07       Impact factor: 5.156

6.  Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromboembolic pulmonary hypertension.

Authors:  Jan K Hennigs; Hans Jörg Baumann; Nicole Lüneburg; Gesine Quast; Lars Harbaum; Jan Heyckendorf; Karsten Sydow; Bernhard Schulte-Hubbert; Michael Halank; Hans Klose
Journal:  Sci Rep       Date:  2014-04-28       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.